Study details
Enrolling now
A Study of Olomorasib (LY3537982) in Healthy Participants
Eli Lilly and Company
NCT IDNCT07439250ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–55
Locations
1 site in FL
What this study is about
This Phase 1 study is testing Fluconazole in people with healthy volunteers. The primary outcome being measured is Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
fluconazole
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib, Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olomorasib